双相[18F]氟比他班PET在行为变异型额颞叶痴呆中的可行性研究
本研究纳入8例行为变异型额颞叶痴呆(bvFTD)患者,均接受[18F]氟比他班和[18F]FDG PET扫描,另10例健康对照和10例阿尔茨海默病(AD)患者仅接受氟比他班PET。结果显示氟比他班注射后2-5分钟时间窗的早期摄取与FDG SUVR相关性最高(Pearson r=0.79,p=0.02),盲法视觉评分鉴别bvFTD的敏感度75%、特异度85%,提示动态氟比他班扫描可作为双相生物标志物。
要点
- 氟比他班早期2-5分钟摄取与FDG代谢数据相关性最高(r=0.79,p=0.02)。
- 伪FDG图像视觉评分鉴别bvFTD敏感度75%、特异度85%。
- 动态氟比他班双相扫描或可替代单独FDG-PET用于鉴别FTD与AD。
核心结论
- 早期相氟比他班摄取显示bvFTD患者额叶灌注减低,与FDG代谢发现相似。
- 动态氟比他班扫描可作为双相生物标志物,用于区分FTD与AD及认知正常老年人,在疑难痴呆病例中可免除单独FDG-PET扫描。
研究设计与样本
- 8例bvFTD患者接受[18F]氟比他班和[18F]FDG-PET扫描。
- 10例健康对照和10例AD患者仅接受氟比他班PET。
- PET数据注射后动态采集60分钟。
- 利用bvFTD数据定义与真实FDG SUVR(40-60分钟)在复合新皮层FTD区域相关性最大的氟比他班伪代谢时间窗。
主要发现
- 氟比他班PET注射后2-5分钟时间窗与FDG数据相关性最大(Pearson r=0.79,p=0.02)。
- 伪FDG图像与实际FDG数据内部一致性高,视觉上与bvFTD患者低代谢模式一致。
- 盲法视觉评分伪FDG图像鉴别bvFTD的敏感度75%、特异度85%,与既往FDG数据报道一致。
关键数值与推荐
- 氟比他班早期相最优时间窗为注射后2-5分钟,与FDG SUVR(40-60分钟)相关性Pearson r=0.79(p=0.02)。
- 伪FDG图像盲法视觉评分鉴别bvFTD敏感度75%、特异度85%。
临床怎么用
- 动态氟比他班PET扫描可同时提供早期灌注相关伪代谢信息和晚期Aβ病理信息,实现双相评估。
- 在疑难痴呆病例中,双相氟比他班扫描或可替代单独的FDG-PET扫描以区分FTD与AD及认知正常老年人。
局限性
- bvFTD患者样本量仅8例,结论需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The PET tracer [18F]florbetapir is a specific fibrillar amyloid-beta (Aβ) biomarker. During the late scan phase (> 40 min), it provides pathological information about Aβ status. Early scan phase (0-10 min) can provide FDG-'like' information. The current investigation tested the feasibility of using florbetapir as a dual-phase biomarker in behavioural variant frontotemporal dementia (bvFTD). METHODS: Eight bvFTD patients underwent [18F]florbetapir and [18]FDG-PET scans. Additionally, ten healthy controls and ten AD patients underwent florbetapir-PET only. PET data were acquired dynamically for 60-min post-injection. The bvFTD PET data were used to define an optimal time window, representing blood flow-related pseudo-metabolism ('pseudo-FDG'), of florbetapir data that maximally correlated with the corresponding real FDG SUVR (40-60 min) in a composite neocortical FTD region. RESULTS: A 2 to 5-min time window post-injection of the florbetapir-PET data provided the largest correlation (Pearson's r = 0.79, p = 0.02) to the FDG data. The pseudo-FDG images demonstrated strong internal consistency with actual FDG data and were also visually consistent with the bvFTD patients' hypometabolic profiles. The ability to identify bvFTD from blind visual rating of pseudo-FDG images was consistent with previous reports using FDG data (sensitivity = 75%, specificity = 85%). CONCLUSIONS: This investigation demonstrates that early phase florbetapir uptake shows a reduction of frontal lobe perfusion in bvFTD, similar to metabolic findings with FDG. Thus, dynamic florbetapir scans can serve as a dual-phase biomarker in dementia patients to distinguish FTD from AD and cognitively normal elderly, removing the need for a separate FDG-PET scan in challenging dementia cases.
引用
- Asghar M, Hinz R, Herholz K, et al. Dual-phase [18F]florbetapir in frontotemporal dementia. Eur J Nucl Med Mol Imaging. 2018. PMID: 30569187. doi:10.1007/s00259-018-4238-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。